Indeed, Defendant Matthew Kapusta, the Company's Chief Executive Officer, assured investors of the Company's alignment with the FDA during calls with investors on June 2, 2025, and July 29, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results